Geron Corporation (NASDAQ: GERN) Proclaims Publication of IMbark Phase 2 information in Journal of Clinical Oncology

Geron Corporation (NASDAQ: GERN), a late-stage scientific biopharmaceutical company, today publicized the publication of information from the IMbark Phase 2 scientific test in the Journal of Clinical Oncology in a document entitled, “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.” The publication highlights the scientific payback observed in the reading, including indication reply and overall endurance and the proof of disease-modifying action from biomarker and bone marrow fibrosis appraisal.

The publication reports effectiveness, security, and biomarker consequences from the IMbark Phase 2 scientific test and is obtainable online. As affirmed in the paper, IMbark tested two imetelstat doses, and the 9.4 mg/kg dose every three weeks established scientific payback in indication reply tempo, with an adequate security outline for this poor-risk JAKi relapsed/refractory MF patient inhabitants. 

IMpactMF is an open tag, randomized, proscribed Phase 3 scientific test with registration intention. The test is intended to register about 320 patients with Intermediate-2 or High-risk myelofibrosis who are refractory to prior cure with a JAK inhibitor, also referred to as refractory MF. Patients will be randomized to take delivery of either imetelstat or top obtainable treatment. The primary endpoint is largely endurance. Critical secondary endpoints include indication reply, spleen reply, progression-free endurance, total reply, incomplete reply, scientific enhancement, duration of reply, security, pharmacokinetics, and patient description results.

Geron Corporation recently declared its First Quarter 2021 consequences

This quarter, the company reported a net pasting of $27.8 million, or $0.09 per share, compared to $16.4 million, or $0.08 per share, for a similar period in 2020.

Income for the first quarter of 2021 was $137,000 compared to $52,000 for a similar period in 2020. Fee revenues in 2021 and 2020 first and foremost reproduce predictable royalties from the sale of cell-based study goods from the company’s divested stem cell possessions. 

Leave a Comment

Your email address will not be published.